1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Hunan Warrant Pharmaceutical Co., Ltd. Class A

Hunan Warrant Pharmaceutical Co., Ltd. Class A

SSSE:688799
47.85
CNY
+0.07
(+0.15%)
0.86EPS
47.24P/E
6.00BMarket Cap
Oct 31Next Earn
2013 Y
2014 Y
2015 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.72
3.04
2.63
3.81
6.24
8.38
9.64
10.24
9.85
10.9
10.75
11.43
11.01
Basic EPS, GAAP
0.29
0.34
0.19
0.61
0.9
1.18
1.47
1.44
1.39
1.61
1.25
1.81
0.95
Free Cash Flow per Basic Share
- -
- -
- -
0.19
0.3
0.94
0.52
0.2
0.18
0.83
-0.7
-1.67
- -
Dividend per Share
0.03
0.03
0.02
0.02
0.01
0.36
0.36
- -
0.5
0.64
0.66
0.48
0.6
Book Value per Share
1.31
2.4
2.91
3.9
4.66
5.62
6.74
11.27
12.16
13.12
13.73
15.56
15.89
Tangible Book Value per Share
1.19
1.87
2.45
3.46
4.22
5.2
6.33
10.83
11.29
12.29
12.07
14.16
14.38
Basic Weighted Avg Shares
71
81
97
98
98
98
99
112
131
131
131
132
132
Sales/Revenue/Turnover
194
247
256
375
613
825
951
1,147
1,293
1,433
1,413
1,504
1,457
Operating Margin (%)
12.5
14.55
14.27
16.44
17.56
100
18.07
15.76
14.49
16.08
12.44
11.01
10.53
Depreciation Expense
- -
- -
- -
19
23
9
30
34
49
61
69
71
- -
Net Income, GAAP
21
28
19
60
88
116
145
161
183
211
164
238
126
Effective Tax Rate (%)
8.04
15.6
13.69
16.7
15.01
9.12
11.83
10.7
11.07
16.03
14.17
5.31
6
Profit Margin (%)
10.77
11.3
7.34
15.94
14.43
14.07
15.26
14.02
14.14
14.75
11.63
15.84
8.63
Working Capital
47
84
52
-7
43
127
199
946
954
1,013
1,014
766
690
LT Debt
- -
20
18
- -
- -
- -
- -
- -
- -
17
114
498
773
Total Equity
158
265
287
384
458
553
663
1,479
1,659
1,768
1,823
2,043
2,124
Return on Invested Capital (%)
- -
9.91
5.53
12.68
19.84
22.52
23.03
15.13
11.13
11.55
7.43
10.15
4.88
Return on Capital (%)
- -
12.3
6.63
16.85
20.18
22.93
23.77
15.01
12.25
13.33
10.19
11.12
5.42
Return on Common Equity (%)
- -
15.26
7.17
17.83
21.02
22.94
23.85
15.01
11.89
12.73
9.32
12.39
6.32

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
1
1
LT Borrowings
498
672
772
LT Finance Leases
- -
- -
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
131
131
134
Market Capitalization
6,264
7,221
5,996

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,176
1,107
1,130
Cash, Cash Equivalents & STI
214
208
289
Accounts Receivable, Net
210
175
189
Inventories
392
391
388
Total Current Liabilities
411
391
439
Payables & Accruals
- -
- -
- -
ST Debt
- -
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
25.9%
31.4%
12.08%
Free Cash Flow
- -
52.43%
140.18%
Net Income, GAAP
35.3%
12.59%
45.01%
Sales/Revenue/Turnover
21.28%
9.85%
6.46%
Total Cash Common Dividend
- -
- -
-27.08%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
373
366
331
344
1,413
2025
336
377
- -
418
1,504
2026
325
336
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.46
0.4
0.35
0.04
1.25
2025
0.31
0.23
- -
0.24
1.81
2026
0.2
0.29
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
0.65
0.66
2025
0.01
0.44
- -
0.02
0.48
2026
0.03
0.12
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ben Dong Huang
Full Time Employees
1,291
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Building C7 Changsha HU China 410006
IPO Date
Jul 13, 2021
Website
warrant.com.cn
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Hunan Warrant Pharmaceutical Co., Ltd. (688799: SS) manufactures and sells pharmaceutical products in China, primarily engaged in the research, development, production, and distribution of chemical raw materials, chemical preparations, active pharmaceutical ingredients, intermediates, pharmaceutical excipients, and traditional Chinese medicine preparations; its core offerings span medicines for digestive, respiratory, anti-infection, gynecology, cardiovascular, cerebrovascular, immunology, nephrology, immune and kidney disorders, obstetrics, and other therapeutic areas, including specific products such as mycophenolate mofetil, fosfomycin trometamol, faropenem sodium, entecavir, docusate sodium, pantoprazole sodium, and herbal extracts. Founded in 2001 and headquartered in Changsha, Hunan province at Building C6-C7, Minmetals Lugu Science and Technology Park, No. 28 Lutian Road, the company operates multiple production bases and R&D centers, serving domestic markets across East China, South China, Central China, and other regions, with growing overseas sales; it maintains approximately 1,238 employees and focuses on innovation-driven growth in chemical drugs, biomacromolecules, and characteristic traditional Chinese medicines. Recent developments include plans announced in 2025 for a 3,000-ton API production base, product registration, and DMF filings to accelerate global API market expansion, alongside securing active pharmaceutical ingredient approval for a respiratory drug in July 2025, China registration approval for another respiratory drug in April 2025, and supplementary application approval for a diabetes medication in August 2024; the company listed on the Shanghai Stock Exchange STAR Market in 2021 and anticipates receiving approximately CNY 500 million in funding.